Circulating Tumor Cells: A Powerful Tool for Real-Time Target Assessment and Strategic Development of Antibody–Drug Conjugates in Cancer Therapy
- Role of CTCs in Liquid Biopsy: Overview of circulating tumor cells as accessible, dynamic biomarkers in oncology.
- Target Antigen Expression on CTCs: Evaluating ADC-relevant targets (e.g., HER2, TROP2) in real-time to guide therapy selection.
- Potential role of CTC profiling in ADC clinical trials and practice.
- Presenting new proof-of-concept automated IHC workflow for HER2, TROP2, and PSMA